Brainstorm Cell Therapeutics Inc. (BCLI)
OTCMKTS · Delayed Price · Currency is USD
1.170
-0.030 (-2.50%)
Jul 17, 2025, 7:59 PM EDT
Brainstorm Cell Therapeutics Employees
Brainstorm Cell Therapeutics had 27 employees as of December 31, 2024. The number of employees decreased by 2 or -6.90% compared to the previous year.
Employees
27
Change (1Y)
-2
Growth (1Y)
-6.90%
Revenue / Employee
n/a
Profits / Employee
-$382,276
Market Cap
8.26M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Endo, Inc. | 3,116 |
Tian'an Technology Group | 8 |
Elite Pharmaceuticals | 68 |
Glass House Brands | 374 |
CytoDyn | 9 |
Northwest Biotherapeutics | 25 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Brainstorm Cell Therapeutics News
- 2 days ago - Brainstorm Cell Therapeutics Crashes 42% After Voluntary Nasdaq Delisting Announcement - Benzinga
- 2 days ago - BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB - PRNewsWire
- 12 days ago - FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness - PRNewsWire
- 4 weeks ago - BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn® - PRNewsWire
- 7 weeks ago - BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials - PRNewsWire
- 2 months ago - Brainstorm Cell Therapeutics Inc. (BCLI) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS - PRNewsWire
- 2 months ago - BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire